Hybridoma technology is an important method for monoclonal antibody (mAb) discovery and development. In fact, the majority of FDA-approved mAb therapeutics are derived from mouse hybridomas. Now, human-like transgenic animals, stable rabbit hybridomas, and methods for humanizing mAbs from rare species enable researchers to develop many more therapeutic mAbs.
This white paper explores the benefits of the hybridoma technique and alternative approaches for mAb generation. It also addresses some misconceptions relating to hybridoma technology.
Download this white paper from GenScript to learn more about technologies for producing monoclonal antibodies.
